<--- Back to Details
First PageDocument Content
Clinical medicine / Medicine / Cancer / Cancer treatments / Immunology / Antineoplastic drugs / Ribbon symbolism / Biotechnology / Trastuzumab emtansine / Trastuzumab / Antibody-drug conjugate / Mertansine
Date: 2016-05-25 07:51:34
Clinical medicine
Medicine
Cancer
Cancer treatments
Immunology
Antineoplastic drugs
Ribbon symbolism
Biotechnology
Trastuzumab emtansine
Trastuzumab
Antibody-drug conjugate
Mertansine

Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 217 Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2Breast Cancer

Add to Reading List

Source URL: uu.diva-portal.org

Download Document from Source Website

File Size: 2,95 MB

Share Document on Facebook

Similar Documents

Edorium J Disabil Rehabil 2015;1:9–11. www.edoriumjournals.com/ej/dr Letter to Editors	  Massoni et al. 

Edorium J Disabil Rehabil 2015;1:9–11. www.edoriumjournals.com/ej/dr Letter to Editors Massoni et al. 

DocID: 1ru4d - View Document

Original Research  Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy Elyce Cardonick,

Original Research Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy Elyce Cardonick,

DocID: 1rr4j - View Document

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document

When Patients Win, We All Win™  Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

When Patients Win, We All Win™ Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

DocID: 1rgN5 - View Document

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile.  Photo courtesy of Dina Potter. Sunny Tree. 48

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60".

DocID: 1rePY - View Document